Olverembatinib (HQP1351), used in combination with low-intensity chemotherapy, has shown encouraging therapeutic potential — along with a favorable safety profile — in individuals with newly…
Blood cancer
Blood cancer is a broad term encompassing diseases in which blood cells grow too much or develop abnormally. Typically, blood cancers are classified into three main categories – leukemia, lymphoma, and myeloma – but they can be further divided into dozens of specific types, each with unique features.
A wide range of therapies are available for treating blood cancer, from chemotherapy and targeted therapy to radiation, stem cell transplant, and surgery. When devising a suitable treatment plan for blood cancer, healthcare providers take into account various factors, such as age, overall health, the specific type of blood cancer, and potential treatment side effects.
Latest news
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘ experimental cell therapy being developed…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine CLN-049, which is being developed as a potential treatment…
Komzifti (ziftomenib), a once-daily oral therapy approved for certain people with acute myeloid leukemia (AML), is now included in the National Comprehensive Cancer Network (NCCN)…
Mission Bio has debuted a new laboratory test that enables researchers to simultaneously detect alterations in the genetic code and changes in genetic activity…
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1…
